Expert Review of Hematology最新文献_第6页

Cyclophosphamide and horse anti-thymocyte globulin versus fludarabine, reduced cyclophosphamide and rabbit anti-thymocyte globulin conditioning regimen for allogeneic hematopoietic stem cell transplantation from matched sibling donors in patients with acquired aplastic anemia. 环磷酰胺和马抗胸腺细胞球蛋白与氟达拉滨、减量环磷酰胺和兔抗胸腺细胞球蛋白治疗获得性再生障碍性贫血患者匹配同胞捐献者异基因造血干细胞移植的方案对比。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-08-01 Epub Date: 2024-07-23 DOI: 10.1080/17474086.2024.2381572

Nour Ben Abdeljelil, Insaf Ben Yaiche, Rihab Ouerghi, Lamia Torjemane, Dorra Belloumi, Ines Turki, Sabrine Mekni, Rimel Yousr Kanoun, Tarek Ben Othman, Saloua Ladeb

{"title":"Cyclophosphamide and horse anti-thymocyte globulin versus fludarabine, reduced cyclophosphamide and rabbit anti-thymocyte globulin conditioning regimen for allogeneic hematopoietic stem cell transplantation from matched sibling donors in patients with acquired aplastic anemia.","authors":"Nour Ben Abdeljelil, Insaf Ben Yaiche, Rihab Ouerghi, Lamia Torjemane, Dorra Belloumi, Ines Turki, Sabrine Mekni, Rimel Yousr Kanoun, Tarek Ben Othman, Saloua Ladeb","doi":"10.1080/17474086.2024.2381572","DOIUrl":"10.1080/17474086.2024.2381572","url":null,"abstract":"Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for acquired aplastic anemia (acquired AA) in young patients. The objective of the study was to compare patient outcomes after Cyclophosphamide and horse antithymocyte globulin (Cy-hATG) versus Fludarabine-cyclophosphamide and rabbit ATG (Flu-Cy-rATG) as part of conditioning regimen in allo-HSCT for acquired AA.Research design and methods: Descriptive retrospective study conducted on patients with acquired AA who received allo-HSCT from HLA-matched sibling donors between January 2008 and August 2022 after conditioning regimen with Cy-hATG or Flu-Cy-rATG.Results: A total of 121 patients were enrolled. Cumulative incidence of graft failure was 11.2% in Cy-hATG and 5.3% Flu-Cy-rATG group. There were no significant differences between the two groups in terms of acute GVHD, chronic GVHD, and transplant related mortality. Flu-Cy-rATG group was associated with significantly higher CMV and EBV reactivation(s) compared to Cy-hATG group (p = 0.008 and 0.035, respectively). After a median follow-up of 58 months, estimated overall survival, event-free survival, and graft rejection-free survival were not statistically different between the two groups.Conclusions: In high-risk population, Flu-Cy-rATG is associated with comparable outcomes to Cy-hATG in allo-HSCT from MSD. However, it seems to be associated with significant risk of viral infections.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"527-538"},"PeriodicalIF":2.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can we use biomarkers to identify those at risk of acute pain from sickle cell disease? 我们能否利用生物标志物来识别镰状细胞病急性疼痛的高危人群？

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-08-01 Epub Date: 2024-07-05 DOI: 10.1080/17474086.2024.2372322

Varsha Bhat, Vivien A Sheehan

引用次数: 0

Update on iron supplementation in patients with cancer-related anemia. 癌症相关贫血患者补铁的最新进展。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-08-01 Epub Date: 2024-07-02 DOI: 10.1080/17474086.2024.2375265

George M Rodgers

{"title":"Update on iron supplementation in patients with cancer-related anemia.","authors":"George M Rodgers","doi":"10.1080/17474086.2024.2375265","DOIUrl":"10.1080/17474086.2024.2375265","url":null,"abstract":"Introduction: Numerous clinical trials affirm the efficacy and safety of IV iron to treat cancer-related anemia (CRA). Nonetheless, evaluation and treatment of CRA remains suboptimal.Areas covered: This review summarizes CRA therapy with a focus on iron deficiency and its treatment. The literature search was conducted using the National Library of Medicine (PubMed) database from 2004 to 2024. Topics reviewed include CRA pathophysiology, laboratory diagnosis of iron deficiency, a summary of clinical trial results using IV iron to treat CRA, and safety aspects.Expert opinion: Despite overwhelming positive efficacy and safety data, IV iron remains underutilized to treat CRA. This is likely due to persistent (unfounded) concerns about IV iron safety and lack of physician awareness of newer clinical trial data. This leads to poor patient quality of life and patient exposure to anemia treatments that have greater safety risks than IV iron. Solutions to this problem include increased educational efforts and considering alternative treatment models in which other providers separately manage CRA. The recent availability of new oral iron therapy products that are effective in treating anemia of inflammation has the potential to dramatically simplify the treatment of CRA.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"505-514"},"PeriodicalIF":2.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reduction of ristocetin-induced platelet aggregation (RIPA) during storage despite plasma renewal: evidence for hemostatic importance of GPIbα shedding. 尽管血浆可以更新，但储存期间利斯托西汀诱导的血小板聚集（RIPA）会降低：GPIbα脱落对止血的重要性证据。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-07-01 Epub Date: 2024-06-21 DOI: 10.1080/17474086.2024.2370557

Ehteramolsadat Hosseini, Emad Taherabadi, Ali Rajabi, Mehran Ghasemzadeh

{"title":"Reduction of ristocetin-induced platelet aggregation (RIPA) during storage despite plasma renewal: evidence for hemostatic importance of GPIbα shedding.","authors":"Ehteramolsadat Hosseini, Emad Taherabadi, Ali Rajabi, Mehran Ghasemzadeh","doi":"10.1080/17474086.2024.2370557","DOIUrl":"10.1080/17474086.2024.2370557","url":null,"abstract":"Background: Platelet storage is complicated by deleterious changes, among which reduction of ristocetin-induced platelet aggregation (RIPA) has a poorly understood mechanism. The study elucidates the mechanistic roles of all the possible players in this process.Research design and methods: PRP-platelet concentrates were subjected to RIPA, collagen-induced platelet aggregation (CIPA), and flowcytometric analysis of GPIbα and PAC-1 binding from days 0 to 5 of storage. Platelet-poor plasma was subjected to colorimetric assays for glucose/LDH evaluation and automatic analyzer to examine VWF antigen and activity.Results: From day three of platelet storage, reducing CIPA but not RIPA was correlated with the reduction of both metabolic state and integrin activity. RIPA reduction was directly related to the decreased levels of total-content/expression of GPIbα, and inversely related to its shedding levels during storage. Re-suspension of 5-day stored platelet in fresh plasma compensated CIPA, but not RIPA. VWF concentration and its activity did not change during storage while they had no correlation with RIPA.Conclusions: This study identified the irreversible loss of platelet GPIbα, but not VWF status, as the primary cause of the storage-dependent decrease of RIPA. Unlike CIPA, this observation was not compensated by plasma refreshment, suggesting that some evidence of PSL may not be recovered after transfusion.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"391-403"},"PeriodicalIF":2.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 更正。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-07-01 Epub Date: 2024-06-18 DOI: 10.1080/17474086.2024.2370092

引用次数: 0

Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase? 50毫克/天是新诊断的慢性粒细胞白血病慢性期患者服用达沙替尼的新标准剂量吗？

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-07-01 Epub Date: 2024-06-25 DOI: 10.1080/17474086.2024.2370556

Betül Saydan, Deniz Özmen, Ahmet Emre Eşkazan

引用次数: 0

Clinical presentation and management of atypical hemolytic uremic syndrome in Latin America: a narrative review of the literature. 拉丁美洲非典型溶血性尿毒症综合征的临床表现和治疗：文献综述。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-07-01 Epub Date: 2024-06-12 DOI: 10.1080/17474086.2024.2365169

R A Sepúlveda Palamara, L G Modelli de Andrade, R M Fortunato, B Gómez, J F Nieto-Ríos

{"title":"Clinical presentation and management of atypical hemolytic uremic syndrome in Latin America: a narrative review of the literature.","authors":"R A Sepúlveda Palamara, L G Modelli de Andrade, R M Fortunato, B Gómez, J F Nieto-Ríos","doi":"10.1080/17474086.2024.2365169","DOIUrl":"10.1080/17474086.2024.2365169","url":null,"abstract":"Introduction: Comprehensive information about atypical hemolytic uremic syndrome (aHUS) is relatively scarce outside of Europe and North America. This narrative review assembles available published data about the clinical presentation and management of aHUS in Latin America.Areas covered: A search conducted in February 2023 of the MEDLINE (from inception), Embase (from inception), and LILACS/IBECS (1950 to 2023) databases using search terms 'atypical hemolytic uremic syndrome' and 'Latin America' and their variations retrieved 51 records (full papers and conference abstracts) published in English, Spanish, or Portuguese. After de-duplication, manual screening of titles/abstracts and addition of author-known articles, 25 articles were included of which 17 (68%) are full papers. All articles were published during the years 2013-2022. Articles include cohort studies, a registry analysis, and case reports from Argentina, Brazil, Chile and Columbia. Overall, Latin American patients with aHUS present the classic epidemiological, clinical, and genetic characteristics associated with this condition as described in other world regions. Depending on the country and time of reporting, aHUS in Latin America was treated mainly with plasma therapy and/or eculizumab. Where reported, eculizumab substantially improved aHUS-related outcomes in almost all adult and pediatric patients.Expert opinion: Eculizumab has dramatically altered the natural course of aHUS, improving prognosis and patient outcomes. Addressing economic challenges and investing in healthcare infrastructure will be essential to implement strategies for timely detection and early treatment of aHUS in Latin America.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"361-374"},"PeriodicalIF":2.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141261426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is intensive chemotherapy and allogeneic stem cell transplantation mandatory for curing Philadelphia chromosome-positive acute lymphoblastic leukemia in young patients in the era of multitarget agents? 多靶点药物时代，年轻患者是否必须接受强化化疗和异基因干细胞移植才能治愈费城染色体阳性急性淋巴细胞白血病？

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-07-01 Epub Date: 2024-05-20 DOI: 10.1080/17474086.2024.2357273

Sang Kyun Sohn, Jung Min Lee, Youngeun Jang, Yunji Lee, Jihyun Na, Hee Jeong Cho, Joon Ho Moon, Dong Won Baek

{"title":"Is intensive chemotherapy and allogeneic stem cell transplantation mandatory for curing Philadelphia chromosome-positive acute lymphoblastic leukemia in young patients in the era of multitarget agents?","authors":"Sang Kyun Sohn, Jung Min Lee, Youngeun Jang, Yunji Lee, Jihyun Na, Hee Jeong Cho, Joon Ho Moon, Dong Won Baek","doi":"10.1080/17474086.2024.2357273","DOIUrl":"10.1080/17474086.2024.2357273","url":null,"abstract":"Introduction: The treatment outcomes for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) have improved with various tyrosine kinase inhibitors (TKIs) and bispecific T-cell engagers. Although allogeneic stem cell transplantation (allo-SCT) is the standard treatment for young patients with Ph+ALL, its role remains debatable in the era of TKIs and blinatumomab.Areas covered: There are some issues regarding Ph+ALL. First, do young patients require intensive chemotherapy (IC) in the era of multitarget agents? Second, which TKI is preferred for frontline therapy? Third, should allo-SCT be performed in patients achieving complete remission with ponatinib and IC? Fourth, can chemo-free treatment lead to a cure without allo-SCT? We searched relevant literature from the last 30 years on PubMed; reviewed the role of chemo-free therapies and combinations of ponatinib and IC; and assessed the necessity of allo-SCT in young patients with Ph+ALL.Expert opinion: Allo-SCT may not be needed, even in young patients with Ph+ALL treated with ponatinib-based IC or combined ponatinib and blinatumomab as frontline therapy. When adopting a ponatinib-based chemo-minimized regimen for induction, allo-SCT is needed with posttransplant ponatinib maintenance. Continuous exposure to ponatinib at pre- or post-transplant is regarded as one of the most important factor for the success of treatment.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"353-359"},"PeriodicalIF":2.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140957104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease. 针对新诊断出的冷凝集素病患者的管理算法不断发展。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-07-01 Epub Date: 2024-06-13 DOI: 10.1080/17474086.2024.2366540

Wilma Barcellini, Bruno Fattizzo

{"title":"The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease.","authors":"Wilma Barcellini, Bruno Fattizzo","doi":"10.1080/17474086.2024.2366540","DOIUrl":"10.1080/17474086.2024.2366540","url":null,"abstract":"Introduction: Cold agglutinin disease (CAD) is driven by IgM autoantibodies reactive at <37°C and able to fix complement. The activation of the classical complement pathway leads to C3-mediated extravascular hemolysis in the liver and to intravascular hemolytic crises in case of complement amplifying conditions. C3 positivity at direct Coombs test along with high titer agglutins are required for the diagnosis. Treatment is less standardized.Areas covered: This review recapitulates CAD diagnosis and then focus on the evolving management of the disease. Both current approach and novel targeted drugs are discussed. Literature search was conducted in PubMed and Scopus from 2000 to 2024 using 'CAD' and 'autoimmune hemolytic anemia' as keywords.Expert opinion: Rituximab represents the frontline approach in patients with symptomatic anemia or disabling cold-induced peripheral symptoms and is effective in 50-60% of cases. Refractory/relapsing patients are an unmet need and may now benefit from complement inhibitors, particularly the anti-C1s sutimlimab, effective in controlling hemolysis thus improving anemia in >80% of patients, but not active on cold-induced peripheral symptoms. Novel drugs include long-acting complement inhibitors, plasma cells, and B-cell targeting agents (proteasome inhibitors, anti-CD38, BTKi, PI3Ki, anti-BAFF). Combination therapy may be the future answer to CAD unmet needs.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"287-294"},"PeriodicalIF":2.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this? 免疫疗法时代的抗BCMA CAR-T细胞疗法和双特异性抗体：我们准备好了吗？

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-07-01 Epub Date: 2024-05-21 DOI: 10.1080/17474086.2024.2357274

Massimo Martino, Barbara Gamberi, Elisabetta Antonioli, Sara Aquino, Roberta Della Pepa, Lara Malerba, Silvia Mangiacavalli, Sara Pezzatti, Sara Bringhen, Elena Zamagni

{"title":"Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?","authors":"Massimo Martino, Barbara Gamberi, Elisabetta Antonioli, Sara Aquino, Roberta Della Pepa, Lara Malerba, Silvia Mangiacavalli, Sara Pezzatti, Sara Bringhen, Elena Zamagni","doi":"10.1080/17474086.2024.2357274","DOIUrl":"10.1080/17474086.2024.2357274","url":null,"abstract":"Introduction: Therapeutic strategies against multiple myeloma (MM) have evolved dramatically in recent decades, with unprecedent results in the treatment landscape, culminating in the recent incorporation of novel agents in the anti-myeloma armamentarium.Areas covered: BCMA represents one of the most promising targets in MM and currently available immune approaches, either approved or under active investigation, are clearly showing their greater potential over standard regimens. In this context, immunotherapies based on chimeric antigen receptor (CAR)-engineered T-cells and bispecific antibodies (BsAbs) have taken center stage, being the ones that are yielding the most promising results in clinical trials. This review focuses on the current landscape of BsAbs and CAR-T, summarizing the latest advances and possible future developments.Expert opinion: CAR-T and BsAbs anti-BCMA strategies represent breakthrough therapies against MM. However, their inclusion in clinical practice is almost feared, due to the associated limitations, some of which have been addressed here. Meanwhile, all the efforts should be focused on individualizing and choosing the most suitable candidates for each treatment and to understand how to combine, or sequence, these therapies to improve efficacy and minimize toxicity, especially for those patients with limited available treatment options.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"375-390"},"PeriodicalIF":2.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141070689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0